檢索結果 - Cho‐Ming Loi
- Showing 1 - 3 results of 3
-
1
-
2
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth 由 Brion W. Murray, Chuangxing Guo, Joseph Piraino, John Westwick, Cathy Zhang, Jane E. Lamerdin, Eleanor Dagostino, Daniel Knighton, Cho‐Ming Loi, Michael Zager, Eugenia Kraynov, Ian Popoff, James G. Christensen, Ricardo Martinez, Susan E. Kephart, Joseph Marakovits, Shannon Karlicek, Simon Bergqvist, Tod Smeal
出版 2010Artigo -
3
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor 由 Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus, Peter Ellis, Erin Trachet, Amy M. Delaney, Patricia J. Harvey, Teresa A. Ellis, Danielle M. Amato, James M. Nelson, David W. Fry, Tong Zhu, Cho‐Ming Loi, Stephen A. Fakhoury, Kevin M. Schlosser, Karen E. Sexton, R. Thomas Winters, Jessica E. Reed, Alex Bridges, Daniel J. Lettiere, Deborah A. Baker, Jianxin Yang, Helen T. Lee, Haile Tecle, Patrick W. Vincent
出版 2008Artigo
相關主題
Chemistry
Biochemistry
Biology
Cancer research
Pharmacology
Signal transduction
Cancer
Cell
Cell biology
Cell cycle
Cell growth
Cerivastatin
Cholesterol
ERBB3
Effector
Endocrinology
Epidermal growth factor receptor
ErbB
Erlotinib
Gefitinib
Genetics
Internal medicine
Isometric exercise
Kinase
Medicine
Pharmacokinetics
Phosphorylation
Pravastatin
Quadriceps femoris muscle
Receptor